TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E [28-217](Homo sapiens (Human))
Pic Therapeutics
US Patent
Pic Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:Test compounds (3.43 mM stock in DMSO) were diluted 2-fold in series in DMSO (10 concentration points). Compound solutions (1.2 μl/well) were ad...More data for this Ligand-Target Pair